Patent Assignment
Reel/Frame 069715/0719
Corrective Assignment to Correct the Correct the Box Titled"This Document Serves as an Oath/Declaration (37 Cfr 1.63)" Was Erroneously Checked and This Box Should Not Have Been Checked, Previously Recorded at Reel: 67607 Frame: 108. Assignor(S) Hereby Confirms the Security Interest.
Recorded: 2024-12-11
Pages: 24
Assignor
OMEROS CORPORATION
Executed: 2024-06-03
Assignee
WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
500 DELAWARE AVENUE, 11TH FLOOR, WILMINGTON, DELAWARE, 19801
Covered Properties
(119)
Generation of Anti-FN14 Monoclonal Antibodies by Ex-Vivo Accelerated Antibody Evolution
Composition and Method for Diversification of Target Sequences
Generation of Anti-FN14 Monoclonal Antibodies by Ex-Vivo Accelerated Antibody Evolution
Anti-FZD10 Monoclonal Antibodies and Methods for Their Use
Anti-FZD10 Monoclonal Antibodies and Methods for Their Use
Monoclonal Antibodies, Compositions and Methods for Detecting Mucin-Like Protein (Mlp) as a Biomarker for Ovarian and Pancreatic Cancer
Biodegradable Triblock Copolymers, Synthesis Methods Therefore, and Hydrogels and Biomaterials Made There From
Mixed Micelles
Mixed Micelles
Genetically Modified Non-Human Mammals and Cells
Genetically Modified Non-Human Mammals and Cells
Methods for Treating Conditions Associated with Masp-2 Dependent Complement Activation
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application:
18/152,536 →
Publication:
US US20230391889A1
Methods for Treating Disseminated Intravascular Coagulation by Inhibiting Masp-2 Dependent Complement Activation
Methods for Treating Conditions Associated with Masp-2 Dependent Complement Activation
Methods for Treating Conditions Associated with Masp-2 Dependent Complement Activation
Methods for Treating Conditions Associated with Masp-2 Dependent Complement Activation
Application:
18/474,631 →
Publication:
US US20240228665A1
Compositions for Inhibiting Masp-2 Dependent Complement Activation
Compositions for Inhibiting Masp-2 Dependent Complement Activation
Compositions for Inhibiting Masp-2 Dependent Complement Activation
Cooling Sleeve and Tourniquet
Application:
16/084,896 →
Publication:
US US20190076294A1
Compositions for Inhibiting Masp-2 Dependent Complement Activation
Compositions for Inhibiting Masp-2 Dependent Complement Activation
Application:
18/168,192 →
Publication:
US US20240092938A1
Antibodies to Masp-2
Antibodies to Masp-2
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application:
17/470,386 →
Publication:
US US20220089781A1
Methods for Identifying Inhibitors of Mannan-Binding Lectin Associated Serine Protease (Masp) Proteins and Uses Thereof
Methods for Identifying Inhibitors of Mannan-Binding Lectin-Associated Serine Protease (Masp) Proteins and Uses Thereof
Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Application:
17/498,521 →
Publication:
US US20220242972A1
Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
Methods for Treating Conditions Associated with Masp-2 Dependent Complement Activation
Application:
18/312,891 →
Publication:
US US20240076408A1
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application:
17/372,070 →
Publication:
US US20220002439A1
Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders
Application:
18/474,862 →
Publication:
US US20240254257A1
Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
Application:
16/984,287 →
Publication:
US US20210079117A1
Methods of Inhibiting Masp-2-Dependent Complement Activation in a Subject Suffering from Catastrophic Antiphospholipid Syndrome
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application:
18/051,993 →
Publication:
US US20240124611A1
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application:
18/355,871 →
Publication:
US US20240076409A1
Methods for Inhibiting Angiogenesis in a Subject in Need Thereof
Methods for Inhibiting Angiogenesis in a Subject in Need Thereof
Methods for Inhibiting Angiogenesis in a Subject in Need Thereof
Application:
18/633,379 →
Publication:
US US20240352152A1
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application:
18/628,104 →
Publication:
US US20240343830A1
Methods for Inhibiting Fibrosis in a Subject in Need Thereof
Methods for Inhibiting Fibrosis in a Subject in Need Thereof
Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various Thrombotic Diseases and Disorders
Application:
18/052,371 →
Publication:
US US20230212314A1
Antibodies Specifically Binding to Masp-3 for the Treatment of Various Diseases and Disorders
Nucleic Acids Encoding Antibodies Specifically Binding to Masp-3
Antibodies Specifically Binding to Masp-3 for the Treatment of Various Diseases and Disorders
Antibodies Specifically Binding to Masp-3 for the Treatment of Various Diseases and Disorders
Application:
18/523,203 →
Publication:
US US20240342278A1
Methods for Inhibiting Fibrosis in a Subject in Need Thereof
Application:
17/217,837 →
Publication:
US US20210355236A1
Masp Isoforms as Inhibitors of Complement Activation
Chimeric Inhibitor Molecules of Complement Activation
Chimeric Inhibitor Molecules of Complement Activation
Chimeric Inhibitor Molecules of Complement Activation
Chimeric Inhibitor Molecules of Complement Activation
Chimeric Inhibitor Molecules of Complement Activation
Chimeric Inhibitor Molecules of Complement Activation
Highly Concentrated Low Viscosity Masp-2 Inhibitory Antibody Formulations, Kits, and Methods
Methods for Use of Highly Concentrated Low Viscosity Masp-2 Inhibitory Antibody Formulations and Kits
Application:
18/176,155 →
Publication:
US US20230226178A1
Highly Concentrated Low Viscosity Masp-2 Inhibitory Antibody Formulations, Kits, and Methods of Treating Subjects Suffering from Atypical Hemolytic Syndrome
Application:
18/480,825 →
Publication:
US US20240247078A1
Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell Transplant
Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell Transplant
Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell Transplant
Application:
18/531,118 →
Publication:
US US20240293465A1
Masp-2 Inhibitors and Methods of Use
Masp-2 Inhibitors and Methods of Use
Masp-2 Inhibitors and Methods of Use
Masp-2 Inhibitors and Methods of Use
Masp-2 Inhibitors and Methods of Use
Masp-2 Inhibitors and Methods of Use
Masp-2 Inhibitors and Methods of Use
Methods for Treating and/or Preventing Idiopathic Pneumonia Syndrome (Ips) and/or Capillary Leak Syndrome (Cls) and/or Engraftment Syndrome (Es) and/or Fluid Overload (Fo) Associated with Hematopoietic Stem Cell Transplant
Application:
18/411,789 →
Publication:
US US20240218080A1
Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome
Masp-2 and Masp-3 Inhibitors, and Related Compositions and Methods, for Treatment of Sickle Cell Disease
Application:
18/181,437 →
Publication:
US US20230416406A1
Monoclonal Antibodies, Compositions and Methods for Detecting Complement Factor D
Biomarker for Assessing the Risk of Developing Acute Covid-19 and Post-Acute Covid-19
Application:
17/665,176 →
Publication:
US US20220308056A1
Therapeutic Antibodies That Bind to the Serine Protease Domain of Masp-2 and Uses Thereof
Application:
18/063,018 →
Publication:
US US20230265215A1
Therapeutic Antibodies That Bind to the Serine Protease Domain of Masp-2 and Uses Thereof
Masp-2 Inhibitors and Methods of Use
Application:
63/588,644 →
Therapeutic Methods and Uses for Antibodies to Human Masp-3
Application:
63/507,304 →
Masp-2 Inhibitors and Methods of Use
Application:
63/588,653 →
Therapeutic Methods and Uses for Antibodies to Human Masp-3
Application:
18/498,508 →
Publication:
US US20240228666A1
Masp-2 Inhibitors and Methods of Use
Application:
18/523,642 →
Publication:
US US20240228499A1
PDE10 Inhibitors and Related Compositions and Methods
PDE10 Inhibitors and Related Compositions and Methods
PDE10 Inhibitors and Related Compositions and Methods
PDE10 Inhibitors and Related Compositions and Methods
PDE10 Inhibitors and Related Compositions and Methods
PDE10 Inhibitors and Related Compositions and Methods
PDE10 Inhibitors and Related Compositions and Methods
PDE10 Inhibitors and Related Compositions and Methods
PDE10 Inhibitors and Related Compositions and Methods
Processes and Intermediates for the Preparation of a PDE10 Inhibitor
Solid State Forms of a PDE10 Inhibitor
PDE10 Inhibitors and Related Compositions and Methods
Optically Active PDE10 Inhibitor
Optically Active PDE10 Inhibitor
Use of PDE7 Inhibitors for the Treatment of Movement Disorders
Use of PDE7 Inhibitors for the Treatment of Movement Disorders
Thienopyrazole Derivative Having PDE7 Inhibitory Activity
Thienopyrazole Derivative Having PDE7 Inhibitory Activity
Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
Treatment of Addiction and Impulse-control Disorders Using PDE7 Inhibitors
Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
Application:
17/823,793 →
Publication:
US US20230110784A1
Pde 7 Modulator Compounds
Application:
63/578,039 →
Methods and Compositions for Treating Cancer
Application:
18/451,632 →
Publication:
US US20240307537A1
Cyclooxygenase Inhibitor and Calcium Channel Antagonist Compositions and Methods for Use in Urological Procedures
Cyclooxygenase Inhibitor and Calcium Channel Antagonist Compositions and Methods for Use in Urological Procedures
Compositions and Methods for Prophylaxis and Treatment of Addictions
Compositions and Methods for Prophylaxis and Treatment of Addictions
Compositions and Methods for Prophylaxis and Treatment of Addictions
Rotational Intrathecal Analgesia
Targeted Catalytic Complement-Activating Molecules and Methods of Use Thereof
Application:
17/938,421 →
Publication:
US US20230173091A1
Methods for Inhibiting Fibrosis in a Subject in Need Thereof
Application:
18/656,093 →
Publication:
US US20240424091A1
Antibodies Specifically Binding to Masp-3 for the Treatment of Various Diseases and Disorders
Related Assignments
(18)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Apr 19, 2011
From: SCHWAEBLE, HANS-WILHELM; DUDLER, THOMAS; TEDFORD, CLARK E.; PARENT, JAMES B.
To: OMEROS CORPORATION; UNIVERSITY OF LEICESTER
Reel/Frame 026148/0992 →
Assignment of Assignor's Interest
Aug 30, 2011
From: SCHWAEBLE, HANS-WILHELM; TEDFORD, CLARK E.; PARENT, JAMES B.; DUDLER, THOMAS
To: OMEROS CORPORATION; UNIVERSITY OF LEICESTER
Reel/Frame 026827/0751 →
Assignment of Assignor's Interest
Mar 29, 2012
From: GOMBOTZ, WAYNE R.
To: OMEROS CORPORATION
Reel/Frame 027955/0476 →
Assignment of Assignor's Interest
May 24, 2012
From: PUN, SUZIE; MOUNT, CHRISTOPHER; KIM, TAE HEE; DULKEN, BENJAMIN
To: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Reel/Frame 028274/0500 →
Assignment of Assignor's Interest
Jun 27, 2012
From: LEPPARD, JOHN BENJAMIN; WOOD, CHRISTI L.; CUMMINGS, W. JASON; YABUKI, MUNEHISA
To: OMEROS CORPORATION
Reel/Frame 028454/0050 →
Assignment of Assignor's Interest
Aug 16, 2013
From: ALLISON, DANIEL S.; CUMMINGS, W. JASON; LEPPARD, JOHN B.; TJOELKER, LARRY W.
To: OMEROS CORPORATION
Reel/Frame 031028/0291 →
Assignment of Assignor's Interest
Aug 16, 2013
From: MAIZELS, NANCY
To: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Reel/Frame 031027/0978 →
Corrective Assignment to Correct the 5TH Inventor's Middle Name Previously Recorded on Reel 031028 Frame 0291. Assignor(S) Hereby Confirms the Middle Name of the 5TH Inventor Listed as Louise Should Be Corrected to L.
Aug 20, 2013
From: ALLISON, DANIEL S.; CUMMINGS, W. JASON; LEPPARD, JOHN B.; TJOELKER, LARRY W.
To: OMEROS CORPORATION
Reel/Frame 031049/0956 →
Assignment of Assignor's Interest
Nov 8, 2013
From: CUMMINGS, W. JASON; YABUKI, MUNEHISA; LEPPARD, JOHN B.; WOOD, CHRISTI L.
To: OMEROS CORPORATION
Reel/Frame 031568/0276 →
Assignment of Assignor's Interest
Sep 10, 2015
From: CUTSHALL, NEIL S.; FERGUSON, KENNETH M.; ZUTA, CHARLES PRINCE
To: OMEROS CORPORATION
Reel/Frame 036535/0118 →
Confirmatory License
Jun 22, 2016
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039113/0495 →
Security Interest
Nov 7, 2016
From: OMEROS CORPORATION
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 040575/0110 →
Assignment of Assignor's Interest
Sep 14, 2017
From: DEMOPULOS, GREGORY A.; OMEROS CORPORATION
To: OMEROS CORPORATION; UNIVERSITY OF LEICESTER
Reel/Frame 043595/0689 →
Assignment of Assignor's Interest
Sep 14, 2017
From: SCHWAEBLE, HANS-WILHELM; UNIVERSITY OF LEICESTER
To: OMEROS CORPORATION; UNIVERSITY OF LEICESTER
Reel/Frame 043595/0700 →
Security Interest
Jul 3, 2018
From: OMEROS CORPORATION
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 046491/0017 →
Release of Security Interest
Nov 15, 2018
From: CRG SERVICING LLC
To: OMEROS CORPORATION
Reel/Frame 047573/0577 →
Security Interest
Jun 3, 2024
From: OMEROS CORPORATION
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 067607/0108 →
Release of Security Interest
Nov 25, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: OMEROS CORPORATION
Reel/Frame 073705/0970 →